Fida Biosystems
Brian Sørensen has extensive work experience in various industries. Brian started their career as the General IP Counsel at LEGO A/S in 1996, later transitioning to the role of Management Assistant to the CEO and COO. In 2002, they joined LEGO SpA as the Operations Director. From 2005 to 2008, they served as the President of ASI Modulex, Inc.
In 2009, Brian became the Managing Director and co-owner of AROS Applied Biotechnology A/S until 2013 when they joined Marselis Advokater as an Erhvervsadvokat and Partner, specializing in corporate law.
Brian then ventured into the biotechnology sector, starting with their role as Co-Owner and member of the Board at Timeline Bioresearch AB / Pipeline Bioresearch ApS in 2016. Brian also co-founded Colorcloudstudioknit the same year.
In 2017, Brian became the Chairman of the Board at BioXpedia A/S, a company providing high-throughput sample preparation and multiomic screening.
In 2018, Brian assumed the position of Chairman of the Board at Insano Holding ApS. Currently, they hold the position of CEO at Fida Biosystem, a company that offers innovative protein quantification and characterization solutions.
Throughout their career, Brian has demonstrated expertise in various roles and industries, particularly in biotechnology and corporate law.
Brian Sørensen completed their secondary education at Rødkilde Gymnasium from 1982 to 1984. Brian then pursued a Master's degree in Law Jura at Aarhus University from 1984 to 1988.
Fida Biosystems
Fida Biosystems offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.